Trial Profile

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors Acadia Pharmaceuticals

Most Recent Events

01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
23 Sep 2019 According to an ACADIA Pharmaceuticals media release, Primary endpoint (Change from Baseline to Week 8 in the Hamilton Depression Scale -17 items (HAMD-17) total score) has been met.
23 Sep 2019 Results presented in an ACADIA Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com